Skip to main content

Drug Interactions between aminophylline / guaifenesin and Prevacid NapraPAC

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

naproxen lansoprazole

Applies to: Prevacid NapraPAC (lansoprazole / naproxen) and Prevacid NapraPAC (lansoprazole / naproxen)

GENERALLY AVOID: Theoretically, proton pump inhibitors may decrease the gastrointestinal absorption of enteric-coated naproxen, which requires an acidic environment for dissolution. The proposed mechanism is an increase in gastric pH (i.e. decreased gastric acidity) induced by proton pump inhibitors. In patients treated with proton pump inhibitors, the possibility of a reduced or subtherapeutic response to enteric-coated naproxen should be considered.

MANAGEMENT: Concomitant use of these drugs is generally not recommended.

References

  1. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc

Switch to consumer interaction data

Minor

aminophylline lansoprazole

Applies to: aminophylline / guaifenesin and Prevacid NapraPAC (lansoprazole / naproxen)

Lansoprazole may cause a minor decrease in the area under the plasma concentration-time curve of theophylline and related drugs. This effect appears to be small (approximately a 13% decrease in one study) and may be related either to a reduction in absorption or to enhanced clearance caused by induction of hepatic enzymes by lansoprazole. Dosage adjustment is not believed to be necessary. However, close observation for evidence of altered methylxanthine effect is recommended.

References

  1. (2001) "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc
  2. Granneman GR, Karol MD, Locke CS (1995) "Pharmacokinetic interaction between lansoprazole and theophylline." Ther Drug Monit, 17, p. 460-4
  3. Kokufu T, Ihara N, Sugioka N, Koyama H, Ohta T, Mori S, Nakajima K (1995) "Effects of lansoprazole on pharmacokinetics and metabolism of theophylline." Eur J Clin Pharmacol, 48, p. 391-5
  4. Ko JW, Jang IJ, Shin JG, Nam SK, Shin SG, Flockhart DA (1999) "Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers." Clin Pharmacol Ther, 65, p. 606-14
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

naproxen food

Applies to: Prevacid NapraPAC (lansoprazole / naproxen)

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Moderate

aminophylline food

Applies to: aminophylline / guaifenesin

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
View all 7 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer